首页> 美国卫生研究院文献>International Journal of Nanomedicine >Preparation, characterization, and in ovo vaccination of dextran-spermine nanoparticle DNA vaccine coexpressing the fusion and hemagglutinin genes against Newcastle disease
【2h】

Preparation, characterization, and in ovo vaccination of dextran-spermine nanoparticle DNA vaccine coexpressing the fusion and hemagglutinin genes against Newcastle disease

机译:共表达融合和血凝素基因抗新城疫的葡聚糖-精胺纳米颗粒DNA疫苗的制备,表征和卵内疫苗接种

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Plasmid DNA (pDNA)-based vaccines have emerged as effective subunit vaccines against viral and bacterial pathogens. In this study, a DNA vaccine, namely plasmid internal ribosome entry site-HN/F, was applied in ovo against Newcastle disease (ND). Vaccination was carried out using the DNA vaccine alone or as a mixture of the pDNA and dextran-spermine (D-SPM), a nanoparticle used for pDNA delivery. The results showed that in ovo vaccination with 40 μg pDNA/egg alone induced high levels of antibody titer (P<0.05) in specific pathogen-free (SPF) chickens at 3 and 4 weeks postvaccination compared to 2 weeks postvaccination. Hemagglutination inhibition (HI) titer was not significantly different between groups injected with 40 μg pDNA + 64 μg D-SPM and 40 μg pDNA at 4 weeks postvaccination (P>0.05). Higher antibody titer was observed in the group immunized with 40 μg pDNA/egg at 4 weeks postvaccination. The findings also showed that vaccination with 40 μg pDNA/egg alone was able to confer protection against Newcastle disease virus strain NDIBS002 in two out of seven SPF chickens. Although the chickens produced antibody titers 3 weeks after in ovo vaccination, it was not sufficient to provide complete protection to the chickens from lethal viral challenge. In addition, vaccination with pDNA/D-SPM complex did not induce high antibody titer when compared with naked pDNA. Therefore, it was concluded that DNA vaccination with plasmid internal ribosome entry site-HN/F can be suitable for in ovo application against ND, whereas D-SPM is not recommended for in ovo gene delivery.
机译:基于质粒DNA(pDNA)的疫苗已成为对抗病毒和细菌病原体的有效亚基疫苗。在这项研究中,DNA疫苗,即质粒内部核糖体进入位点-HN / F,已在卵中用于抗新城疫(ND)。疫苗接种可以单独使用DNA疫苗进行,也可以使用pDNA和葡聚糖-精胺(D-SPM)(用于pDNA递送的纳米颗粒)的混合物进行。结果表明,在单独接种40μgpDNA /蛋的卵内接种后,与接种疫苗后2周相比,在特定的无病原体(SPF)鸡中,高抗体滴度(P <0.05)。接种后4周注射40μgpDNA + 64μgD-SPM和40μgpDNA的组之间的血凝抑制(HI)滴度无显着差异(P> 0.05)。接种疫苗后4周,在用40μgpDNA /鸡蛋免疫的组中观察到较高的抗体滴度。研究结果还表明,仅用40μgpDNA /蛋进行疫苗接种就可以在7只SPF鸡中的2只中提供针对新城疫病毒株NDIBS002的保护。尽管鸡在卵内接种后3周产生了抗体效价,但这不足以为鸡提供完全保护,使其免受致命的病毒攻击。此外,与裸露的pDNA相比,接种pDNA / D-SPM复合物不会诱导高抗体滴度。因此,可以得出结论,用质粒内部核糖体进入位点-HN / F进行DNA疫苗接种可适合于卵对ND的应用,而不建议将D-SPM用于卵基因的递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号